This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
Q1 2021 Poll
During the first quarter of 2021, CLL Society conducted a poll among readers of The CLL Society Tribune about their treatment decisions. There were 188 respondents.
Of the respondents who completed the survey, 51.6% were male and 48.4% were female. The average age of respondents was 68, and the age range was 32 – 92 years of age. Regarding race and ethnicity, 93.3% of respondents identified as White or Caucasian, 1.54% as Hispanic or Latino, 1.54% as Indigenous, American Indian or Alaskan Native, 1% as African American, 1% as Asian American, and 1% as Other. In terms of treatment status, 26.9% are treatment naïve or watch & wait, 35% are undergoing or have completed their first treatment, 19.8% are undergoing or have completed their second treatment, and 17.8% is undergoing or have completed three or more treatments.
Did your doctor present multiple treatment options for you to choose from prior to each treatment?
When asked if the doctor presented multiple treatment options, slightly more have half (52.8%) responded that they had.
Which of the following have ever been presented as treatment options? Please select all that apply:
The largest percentage of respondents selected ibrutinib (22.4%) as the treatment offered to them by their doctor, followed by chemoimmunotherapy (17.3%), and venetoclax (15.4%).
Did you ask your doctor for more information about a specific treatment? Please select all that apply:
For the treatment options that patients asked their doctors about, the largest respondents again selected ibrutinib (19.1%), followed by a tie between venetoclax (15.5%) and clinical trials (15.3%).
Which would best describe the decision-making process surrounding treatment options with your doctor?
When asked which best described the decision-making process surrounding treatment options with your doctor, more than half of respondents (52.8%) stated the doctor offered them options to consider and they shared in the decision-making process.
Did you request a specific CLL treatment from your doctor?
When asked if respondents requested a specific treatment option from their doctors, they majority did not (69.5%).
If yes, which treatment did you request? Please select all that apply:
Of the 30.5% of responded that reported yes, they requested a specific CLL treatment from their doctor, we asked two follow-up questions. As to which treatment option they requested, the highest percentage of respondents selected venetoclax (29.1%), followed by a tie between ibrutinib and clinical trials (19%).
Was your request for a specific treatment granted by your doctor?
Of those that responded yes that they requested a specific CLL treatment from their doctor, we asked if their specific treatment request was granted by the doctor and 87.7% stated yes.
Which treatment(s) did you receive for CLL? Please select all that apply:
We asked all respondents what treatment they received for CLL and the majority of respondents stated ibrutinib (19.9%), followed by venetoclax (15.4%), and then tied by chemoimmunotherapy and those who selected not applicable (14.16%).